Platinib (Pujihua) capsules official instructions and analysis of key medication details

Pralsetinib (Pralsetinib) is an oral small molecule targeted drug, mainly used to treat RET fusion-positive or RET mutation-driven advanced non- Small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other RET related tumors. The drug is a highly selective RET tyrosine kinase inhibitor that can inhibit the proliferation and survival of tumor cells by blocking the abnormal RET signaling pathway, thereby exerting anti-tumor effects. With the promotion of clinical application, understanding the official instructions and key medication details of platinib is of great significance for patients to use the medication safely and rationally.

In terms of usage and dosage, Platinib capsules are recommended to be taken orally once a day, and the dosage needs to be adjusted according to the patient's weight, liver and kidney function, and specific indications. The drug should be swallowed whole and can be taken with food or on an empty stomach, but it is recommended to take it at a fixed time every day to maintain stable blood concentration. If a dose is missed, it should be taken as soon as possible after discovery. However, if it is close to the time of the next dose, skip the missed dose and do not take a double dose at one time. According to the instructions, the treatment course should be continued until the disease progresses or intolerable adverse reactions occur, and the doctor will adjust the medication plan based on imaging and clinical evaluation.

Regarding the safety of Platinib, the instructions list common and serious adverse reactions. Common adverse reactions include hematological abnormalities (such as neutropenia, thrombocytopenia), abnormal liver function, constipation, hypertension, fatigue and muscle pain. Serious adverse reactions may involve interstitial lung disease (ILD), cardiac QT interval prolongation, etc. Patients should regularly monitor blood routine, liver function, electrocardiogram and blood pressure during medication. If any abnormality occurs, they should contact the doctor in time to adjust the dose or temporarily stop medication. The instructions emphasize that caution should be used when concomitantly using drugs that may affect the cardiac QT interval or strong CYP3A4 inhibitors to avoid the risk of drug interactions.

In addition, the use of platinib in special populations requires special attention. Elderly patients, patients with impaired liver and kidney function, and pregnant or lactating women should weigh the pros and cons before use under the guidance of a doctor. Patients should strictly abide by the medication guidelines and avoid increasing or decreasing dosage or discontinuing medication on their own. For patients who plan to become pregnant, they should take effective contraceptive measures during treatment and avoid breastfeeding to prevent potential effects of the drug on the fetus or newborn. Overall, Platinib capsule is a targeted drug targeting RET-driven tumors. Its official instructions provide complete medication specifications and safety tips. Combined with individualized assessment and regular monitoring, the best efficacy can be achieved while ensuring safety.

Reference link:https://www.drugs.com